ZA200604719B - DPP-IV inhibitors - Google Patents

DPP-IV inhibitors

Info

Publication number: ZA200604719B
Authority: ZA; South Africa
Prior art keywords: dpp; inhibitors; compounds; relates; medicament
Prior art date: 2003-12-09

Application number

ZA200604719A

Other languages

English (en)

Inventor

Edwards Paul John

Lopez-Canet Meritxell

Feurer Achim

Cerezo-Galvez Silvia

Matassa Victor Giulio

Nordhoff Sonja

Thiemann Meinolf

Hill Oliver

Original Assignee

Santhera Pharmaceuticals Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-09

Filing date

2006-06-08

Publication date

2007-12-27

2006-06-08 Application filed by Santhera Pharmaceuticals Gmbh filed Critical Santhera Pharmaceuticals Gmbh

2007-12-27 Publication of ZA200604719B publication Critical patent/ZA200604719B/xx

Links

108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 title abstract 2
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 abstract 3
239000003814 drug Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Virology (AREA)
Orthopedic Medicine & Surgery (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)

ZA200604719A 2003-12-09 2006-06-08 DPP-IV inhibitors ZA200604719B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP03028211A EP1541143A1 (en)	2003-12-09	2003-12-09	Dpp-iv inhibitors

Publications (1)

Publication Number	Publication Date
ZA200604719B true ZA200604719B (en)	2007-12-27

Family

ID=34486147

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200604719A ZA200604719B (en)	2003-12-09	2006-06-08	DPP-IV inhibitors

Country Status (24)

Country	Link
US (1)	US20080027035A1 (xx)
EP (2)	EP1541143A1 (xx)
JP (1)	JP2007513910A (xx)
KR (1)	KR100845397B1 (xx)
CN (1)	CN1905868A (xx)
AT (1)	ATE372767T1 (xx)
AU (1)	AU2004296553B2 (xx)
BR (1)	BRPI0417458A (xx)
CA (1)	CA2548742A1 (xx)
CY (1)	CY1106969T1 (xx)
DE (1)	DE602004008895T2 (xx)
DK (1)	DK1613304T3 (xx)
ES (1)	ES2291966T3 (xx)
HK (1)	HK1087022A1 (xx)
HR (1)	HRP20070560T3 (xx)
IL (1)	IL176062A0 (xx)
MX (1)	MXPA06006652A (xx)
NO (1)	NO20062644L (xx)
PL (1)	PL1613304T3 (xx)
PT (1)	PT1613304E (xx)
RU (1)	RU2006119302A (xx)
SI (1)	SI1613304T1 (xx)
WO (1)	WO2005056003A1 (xx)
ZA (1)	ZA200604719B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20040015298A (ko)	2001-06-27	2004-02-18	스미스클라인 비참 코포레이션	디펩티딜 펩티다제 억제제로서의 플루오로피롤리딘
AU2004206812A1 (en)	2003-01-17	2004-08-05	Merck & Co., Inc.	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2513684A1 (en)	2003-01-31	2004-08-19	Merck & Co., Inc.	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2524531A1 (en)	2003-05-14	2004-12-02	Merck And Co., Inc.	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CN1798556A (zh)	2003-06-06	2006-07-05	麦克公司	作为治疗或者预防糖尿病的二肽基肽酶抑制剂的稠合吲哚
CN1809544A (zh)	2003-06-17	2006-07-26	麦克公司	作为二肽基肽酶抑制剂用于治疗或预防糖尿病的环己基甘氨酸衍生物
EP1651623B1 (en)	2003-07-31	2008-12-17	Merck & Co., Inc.	Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US7687492B2 (en)	2004-05-04	2010-03-30	Merck Sharp & Dohme Corp.	1,2,4-Oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US7671073B2 (en)	2004-05-18	2010-03-02	Merck Sharp & Dohme Corp.	Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2006098342A1 (en) *	2005-03-16	2006-09-21	Astellas Pharma Inc.	Piperazinyl compounds
EP2487154B1 (en) *	2005-10-31	2013-10-16	Bristol-Myers Squibb Company	Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
GB0526291D0 (en)	2005-12-23	2006-02-01	Prosidion Ltd	Therapeutic method
US20090156465A1 (en)	2005-12-30	2009-06-18	Sattigeri Jitendra A	Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
US7728146B2 (en)	2006-04-12	2010-06-01	Probiodrug Ag	Enzyme inhibitors
EP1905759A1 (en) *	2006-09-07	2008-04-02	Santhera Pharmaceuticals (Schweiz) AG	N-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide and related compounds as dpp-iv inhibitors for the treatment oftype 2 diabetes mellitus
WO2008028662A1 (en) *	2006-09-07	2008-03-13	Santhera Pharmaceuticals (Schweiz) Ag	N-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide and related compounds as dpp-iv inhibitors for the treatment of type 2 diabetes mellitus
US8278345B2 (en)	2006-11-09	2012-10-02	Probiodrug Ag	Inhibitors of glutaminyl cyclase
US9126987B2 (en)	2006-11-30	2015-09-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase
KR20080071476A (ko) *	2007-01-30	2008-08-04	주식회사 엘지생명과학	신규한 디펩티딜 펩티데이즈 ｉｖ(ｄｐｐ-ｉｖ) 저해제
EP2142514B1 (en)	2007-04-18	2014-12-24	Probiodrug AG	Thiourea derivatives as glutaminyl cyclase inhibitors
KR101007497B1 (ko) *	2007-04-19	2011-01-12	동아제약주식회사	베타 아미노기를 포함하는 ｄｄｐ－ⅳ 저해제, 이의제조방법 및 이를 유효성분으로 함유하는 당뇨 또는 비만예방 및 치료용 약학적 조성물
US7860904B2 (en) *	2007-04-24	2010-12-28	Microsoft Corporation	Standalone execution of incomplete data flows
WO2009003681A1 (en) *	2007-07-02	2009-01-08	Santhera Pharmaceuticals (Schweiz) Ag	Dpp-iv inhibitors
EP2019099A1 (en) *	2007-07-02	2009-01-28	Santhera Pharmaceuticals (Schweiz) AG	Dpp-IV inhibitors
CN102838589B (zh) *	2008-09-23	2014-03-26	成都地奥制药集团有限公司	经甲磺酰化的制备n取代的吡咯烷衍生物的方法
CN101823987B (zh) *	2009-03-06	2014-06-04	中国科学院上海药物研究所	一类新的dpp-ⅳ抑制剂及其制备方法和用途
UA107360C2 (xx)	2009-08-05	2014-12-25	Biogen Idec Inc	Біциклічні арильні аналоги сфінгозин 1-фосфату
BR112012008346B1 (pt)	2009-09-11	2021-12-21	Vivoryon Therapeutics N.V.	Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
EP2542549B1 (en)	2010-03-03	2016-05-11	Probiodrug AG	Inhibitors of glutaminyl cyclase
KR101790806B1 (ko)	2010-03-10	2017-11-20	프로비오드룩 아게	글루타미닐 사이클라제(ｑｃ, ｅｃ 2.3.2.5)의 헤테로사이클릭 억제제
EP2560953B1 (en)	2010-04-21	2016-01-06	Probiodrug AG	Inhibitors of glutaminyl cyclase
ES2929077T3 (es)	2011-02-07	2022-11-24	Biogen Ma Inc	Agentes moduladores de S1P
ES2570167T3 (es)	2011-03-16	2016-05-17	Probiodrug Ag	Derivados de benzimidazol como inhibidores de glutaminil ciclasa
WO2012170702A1 (en)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20160350201A1 (en) *	2015-05-27	2016-12-01	International Business Machines Corporation	Etl data flow design assistance through progressive context matching
AU2016288230A1 (en)	2015-07-02	2018-01-25	Horizon Orphan Llc	ADO-resistant cysteamine analogs and uses thereof
CN105362268A (zh) *	2015-12-15	2016-03-02	上海壹志医药科技有限公司	脱亚甲基小檗碱的药物用途
CN106526047A (zh) *	2016-11-15	2017-03-22	迪沙药业集团有限公司	R‑琥珀酸曲格列汀光学纯度的测定方法
EP3461819B1 (en)	2017-09-29	2020-05-27	Probiodrug AG	Inhibitors of glutaminyl cyclase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6573287B2 (en) *	2001-04-12	2003-06-03	Bristo-Myers Squibb Company	2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
US7098239B2 (en) *	2001-06-20	2006-08-29	Merck & Co., Inc	Dipeptidyl peptidase inhibitors for the treatment of diabetes
DE60209348T2 (de) *	2001-06-20	2006-10-12	Merck & Co., Inc.	Dipeptidylpeptidase-hemmer zur behandlung von diabetes
DE10340800A1 (de) *	2002-12-20	2004-07-01	Merck Patent Gmbh	Funktionalisierung unreaktiver Substrate

2003
- 2003-12-09 EP EP03028211A patent/EP1541143A1/en not_active Withdrawn
2004
- 2004-12-09 PT PT04803694T patent/PT1613304E/pt unknown
- 2004-12-09 RU RU2006119302/04A patent/RU2006119302A/ru not_active Application Discontinuation
- 2004-12-09 AT AT04803694T patent/ATE372767T1/de not_active IP Right Cessation
- 2004-12-09 PL PL04803694T patent/PL1613304T3/pl unknown
- 2004-12-09 JP JP2006543480A patent/JP2007513910A/ja not_active Withdrawn
- 2004-12-09 CN CNA2004800404476A patent/CN1905868A/zh active Pending
- 2004-12-09 EP EP04803694A patent/EP1613304B1/en not_active Expired - Lifetime
- 2004-12-09 US US10/582,054 patent/US20080027035A1/en not_active Abandoned
- 2004-12-09 AU AU2004296553A patent/AU2004296553B2/en not_active Ceased
- 2004-12-09 ES ES04803694T patent/ES2291966T3/es not_active Expired - Lifetime
- 2004-12-09 DE DE602004008895T patent/DE602004008895T2/de not_active Expired - Fee Related
- 2004-12-09 WO PCT/EP2004/014040 patent/WO2005056003A1/en active Application Filing
- 2004-12-09 DK DK04803694T patent/DK1613304T3/da active
- 2004-12-09 CA CA002548742A patent/CA2548742A1/en not_active Abandoned
- 2004-12-09 MX MXPA06006652A patent/MXPA06006652A/es not_active Application Discontinuation
- 2004-12-09 BR BRPI0417458-5A patent/BRPI0417458A/pt not_active IP Right Cessation
- 2004-12-09 SI SI200430469T patent/SI1613304T1/sl unknown
- 2004-12-09 KR KR1020067013752A patent/KR100845397B1/ko not_active Expired - Fee Related
2006
- 2006-05-31 IL IL176062A patent/IL176062A0/en unknown
- 2006-06-08 ZA ZA200604719A patent/ZA200604719B/xx unknown
- 2006-06-08 NO NO20062644A patent/NO20062644L/no not_active Application Discontinuation
- 2006-06-24 HK HK06107175A patent/HK1087022A1/xx not_active IP Right Cessation
2007
- 2007-10-30 CY CY20071101404T patent/CY1106969T1/el unknown
- 2007-12-12 HR HR20070560T patent/HRP20070560T3/xx unknown

Also Published As

Publication number	Publication date
SI1613304T1 (sl)	2007-12-31
CY1106969T1 (el)	2012-09-26
KR100845397B1 (ko)	2008-07-09
EP1613304B1 (en)	2007-09-12
PT1613304E (pt)	2007-11-14
RU2006119302A (ru)	2008-01-20
ES2291966T3 (es)	2008-03-01
US20080027035A1 (en)	2008-01-31
AU2004296553B2 (en)	2008-09-04
BRPI0417458A (pt)	2007-03-13
DE602004008895T2 (de)	2008-06-19
HK1087022A1 (en)	2006-10-06
JP2007513910A (ja)	2007-05-31
MXPA06006652A (es)	2007-02-20
PL1613304T3 (pl)	2008-02-29
EP1613304A1 (en)	2006-01-11
CN1905868A (zh)	2007-01-31
WO2005056003A1 (en)	2005-06-23
IL176062A0 (en)	2006-10-05
HRP20070560T3 (en)	2008-01-31
CA2548742A1 (en)	2005-06-23
NO20062644L (no)	2006-09-07
DK1613304T3 (da)	2008-01-21
KR20060108756A (ko)	2006-10-18
ATE372767T1 (de)	2007-09-15
DE602004008895D1 (en)	2007-10-25
EP1541143A1 (en)	2005-06-15
AU2004296553A1 (en)	2005-06-23

Publication	Publication Date	Title
ZA200604719B (en)	2007-12-27	DPP-IV inhibitors
AP1614A (en)	2006-05-21	New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
MXPA03011039A (es)	2004-03-19	Nuevos compuestos heterociclicos, su preparacion y uso como medicamentos, particularmente como agentes anti-bacterianos.
EP1604989A8 (en)	2006-03-15	DPP-IV inhibitors
ZA200309887B (en)	2004-07-20	Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
WO2006005609A3 (de)	2006-03-16	Substituierte oxindol-derivate und diese enthaltende arzneimittel
WO2003093269A3 (de)	2004-04-08	Substituierte pyrazolo-pyrimidin-4-one
HK1155146A1 (zh)	2012-05-11	作為藥物活性劑的茚衍生物
WO2006048330A8 (en)	2006-10-05	11βετα-hsd1 inhibitors
NO20070089L (no)	2007-01-05	DPP-IV inhibitorer
PL376119A1 (en)	2005-12-12	Novel piperidine derivatives for use in the treatment of chemokine mediated disease states
IL173810A0 (en)	2006-07-05	Imidazopyridine derivatives and pharmaceutical compositions containing the same
TW200500339A (en)	2005-01-01	Pyrrolidine derivatives, and process for the preparation
IL183636A0 (en)	2007-09-20	Quinoline derivative, use and production thereof, and drug containing the same
WO2003106450A8 (de)	2005-02-03	Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
MXPA03009548A (es)	2004-05-24	Arilsulfonamidas como agentes antivirales.
ZA200404752B (en)	2005-04-26	6-aminomorphinane derivatives method for the production and use thereof
MXPA04006266A (es)	2004-09-27	Pirimidotriazinas como inhibidores de fosfatasa.
EP1598341A8 (en)	2006-03-01	DPP-IV inhibitors
HK1096548A1 (en)	2007-06-01	Imidazopyridine-derivatives as inductible no-synthase inhibitors
GEP20084361B (en)	2008-04-29	Piperidinylcarbonyl-pyrro-lidines and their use as melanocortin agonists
MXPA03010120A (es)	2004-03-10	Arilcetonas substituidas.
MXPA04005151A (es)	2004-08-11	Compuestos terapeuticos.
MXPA02001406A (es)	2002-08-12	Heterociclilos-2h-cromenos substituidos.
WO2004024681A3 (fr)	2004-07-01	NOUVEAUX COMPOSES COMPRENANT UN GROUPEMENT THIOCARBONYLSULFANYLE UTILES POUR LA SYNTHESE DE COMPOSES α-PERFLUOROALKYLAMINES PAR VOIE RADICALAIRE